Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.

Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company (MRK – Research Report) yesterday and set a price target of ...

In a report released yesterday, Umer Raffat from Evercore ISI maintained a Buy rating on Merck & Company (MRK – Research Report). The ...

MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...

We recently published a list of 15 Best Dividend Stocks To Buy and Hold. In this article, we are going to take a look at ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...